# Validation and Standardization of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker in Breast Cancer

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2020 · $204,500

## Abstract

Abstract
 Breast cancer is extremely common, striking 1 in 8 American women, and is the second leading cause
of cancer death among women in the U.S. Earlier detection through screening is a fundamental way to improve
survival. Women with dense breasts on screening mammography have increased risk of developing breast
cancer, and increased breast density reduces the sensitivity of mammography for cancer detection. As a result,
a growing number of states have passed legislation mandating that providers inform women if their breast density
is increased, warranting supplemental screening. Dynamic contrast enhanced MRI (DCE-MRI) is the most
sensitive technique for detecting breast cancer, particularly in women with dense breasts. However, overlap in
the appearance of benign and malignant breast lesions on DCE-MRI can produce many false positives, and
there is a clear need to improve the specificity of breast MRI in order to limit the number of unnecessary biopsies
that will result from expanded use of this highly sensitive screening tool. Furthermore, the high costs and safety
concerns of gadolinium-based contrast agents limit the accessibility of breast MRI screening for many women,
so identifying a non-contrast alternative for detecting breast cancer would have strong clinical impact.
 A promising adjunct MRI technique is diffusion-weighted imaging (DWI), which indirectly assesses tissue
microstructure and can provide complementary information to DCE-MRI for lesion characterization. We have
previously demonstrated significant differences in apparent diffusion coefficient (ADC) values between benign
and malignant lesions and that ADC measures can increase the positive predictive value of conventional breast
MRI. We recently confirmed these findings in a multicenter trial (ACRIN 6702). We have also observed that many
mammographically and clinically-occult cancers are visible on DWI without using a contrast agent, suggesting
DWI could provide a faster, less expensive, and safer screening option than DCE-MRI, which is the topic being
explored in the parent grant (NIH R01-CA207290).
 Aims of the proposed study will be to standardize and validate technical approaches to overcome hurdles
in translating ADC as diagnostic biomarker into clinical practice. Image corrections to address known
inaccuracies related to gradient nonlinearities, misregistration and geometric distortion will be implemented, and
methodology for measuring lesion ADC will be optimized to maximize diagnostic performance and reliability. The
assay will be refined using the existing ACRIN 6702 multicenter dataset to ensure wide generalizability and
tested prospectively at several sites. If successful, a standardized ADC assay to more accurately assess the
probability of malignancy at the time of detection would reduce the number of unnecessary (benign) biopsies
performed as a result of breast MRI screening, with or without contrast.

## Key facts

- **NIH application ID:** 10047516
- **Project number:** 3R01CA207290-04S1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Savannah Corrina Partridge
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $204,500
- **Award type:** 3
- **Project period:** 2017-06-01 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10047516

## Citation

> US National Institutes of Health, RePORTER application 10047516, Validation and Standardization of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker in Breast Cancer (3R01CA207290-04S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10047516. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*